SCHEMBL8253620

SCHEMBL8253620

COc1cc(Nc2nccc(-c3cnc(-c4cccnc4)n3C)n2)cc(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 6/20 0.55
▸ PRKCD Q05655 3/20 0.55
▸ ZAP70 P43403 2/20 0.55
▸ PRKD3 O94806 1/20 0.55
▸ PRKCG P05129 1/20 0.55
▸ PRKCB P05771 1/20 0.55
▸ LCK P06239 1/20 0.55
▸ PRKCH P24723 1/20 0.55
▸ PRKCI P41743 1/20 0.55
▸ PRKCE Q02156 1/20 0.55
▸ PRKCQ Q04759 1/20 0.55
▸ PRKCZ Q05513 1/20 0.55
▸ PRKD1 Q15139 1/20 0.55
▸ KDR P35968 5/20 0.54
▸ FLT1 P17948 2/20 0.54
▸ FLT4 P35916 2/20 0.54
▸ CDK2 P24941 3/20 0.53
▸ GSK3B P49841 2/20 0.53
▸ CDK4 P11802 1/20 0.53
▸ ABL1 P00519 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8255847 0.92 PIK3CG (0.59) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL12837140 0.82 ABL1 (0.58) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL8246544 0.82 ABL1 (0.58) PRKCAPRKCDPRKD3PRKCGPRKCB
SCHEMBL8252396 0.81 ABL1 (0.77) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL11929046 0.80 ABL1 (0.53) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL11924749 0.79 ABL1 (0.62) PRKCAPRKCDPRKD3PRKCGPRKCB
SCHEMBL8246547 0.78 ABL1 (0.58) PRKCAPRKCDCDK2GSK3BCDK4
SCHEMBL4164771 0.77 ZAP70 (0.54) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL7474612 0.76 PIK3CG (0.76) PRKCAPRKCDZAP70PRKD3PRKCG
SCHEMBL7466239 0.74 ACVR1 (0.72) PRKCAPRKCDZAP70PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150313881-A1 Therapeutic Methods for Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2015-11-05 — — US disclosed
US-20150313881-A1 Therapeutic Methods for Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2015-11-05 — — US disclosed
US-8501812-B2 Therapeutic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS (US) 2013-08-06 — — US disclosed
US-8501812-B2 Therapeutic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS (US) 2013-08-06 — — US disclosed
US-20120208846-A1 Therapeutic Methods For Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2012-08-16 — — US disclosed
US-20120208846-A1 Therapeutic Methods For Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2012-08-16 — — US disclosed
US-7897572-B1 Theraputic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2011-03-01 — — US disclosed
US-7897572-B1 Theraputic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2011-03-01 — — US disclosed
WO-2006104983-A1 THERAPEUTIC METHODS FOR TYPE I DIABETES UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313881-A1 Therapeutic Methods for Type I Diabetes MAPK9, IAPP, RNASE1 PRKCA 159/4885PRKCD 710/4885ZAP70 1488/4885
US-20120208846-A1 Therapeutic Methods For Type I Diabetes MAPK9, IAPP, RNASE1 PRKCA 159/4885PRKCD 710/4885ZAP70 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback